Purpose: Bisphosphonates have proven effective in reducing pain and skeletal events in bone metastases treatment.
However, there is a long-term complication called osteonecrosis of the jaw, which has been reported for more than a decade. Despite various professional recommendations, there is no international consensus on the best therapeutic strategy. Prevention is crucial, and a multidisciplinary approach must be tailored to each stage of the condition.
Design: We present a case of osteonecrosis of the jaw in a patient with metastatic breast cancer who was receiving
4 mg injectable zoledronic acid.
Result: The patient stopped treatment with zoledronic acid and received systemic treatment (analgesics, antibiotics),
with the resolution of symptoms.
Conclusion: ONJ is a serious condition associated with taking BP that can impact oral health and quality of life.
Our study highlights the effectiveness of systematic treatment in managing ONJ with BP-related alterations.
Preventative measures, such as regular dental consultations, play a vital role in reducing the risk of ONJ.
Multidisciplinary management is essential to addressing the different stages of the condition.

Osteonecrosis Mandible Bisphosphonates Breast cancer